Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs erlotinib as second-line therapy in squamous NSCLC (China)
CTR20131407Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of afatinib in Pulmonary squamous cell carcinoma, sponsored by Boehringer Ingelheim. Started Aug 2014; status: completed.
02
Drugs
afatinib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20131407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131407.